Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31‐gene expression profile test

Objective Although most patients diagnosed with early‐stage cutaneous melanoma (CM) have excellent outcomes, because of the large number diagnosed each year, many will experience recurrence or death. Prognostic testing for CM using the 31‐gene expression profile (31‐GEP) test can benefit patients by...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2023-01, Vol.12 (2), p.2008-2015
Main Authors: Ahmed, Kelli, Siegel, Jennifer J., Morgan‐Linnell, Sonia K., LiPira, Kyleigh
Format: Article
Language:English
Subjects:
31‐GEP test
Attitudes
Cancer
Decision making
Demographics
Gene expression
gene expression profiling
Gene Expression Profiling - methods
Humans
Mann-Whitney U test
Melanoma
Melanoma - diagnosis
Melanoma - genetics
Melanoma - pathology
Melanoma, Cutaneous Malignant
Metastasis
oncology
Prognosis
Skin Neoplasms - diagnosis
Skin Neoplasms - genetics
Skin Neoplasms - pathology
surveys and questionnaires
Transcriptome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Although most patients diagnosed with early‐stage cutaneous melanoma (CM) have excellent outcomes, because of the large number diagnosed each year, many will experience recurrence or death. Prognostic testing for CM using the 31‐gene expression profile (31‐GEP) test can benefit patients by helping guide risk‐appropriate treatment and surveillance plans. We sought to evaluate patients' attitudes toward prognostic testing with the 31‐GEP and assess whether patients experience decision regret about having 31‐GEP testing. Methods A 43‐question survey was distributed by the Melanoma Research Foundation in June–August 2021 to CM patients enrolled in their database. Patients were asked questions regarding their decision to undergo 31‐GEP testing and the extent to which they experienced decision regret using a validated set of Decision Regret Scale questions. Results We analyzed responses from patients diagnosed in 2014 or later (n  = 120). Of these, 28 had received 31‐GEP testing. Most respondents (n  = 108, 90%) desired prognostic information when diagnosed. Of those who received 31‐GEP testing, most felt the results were useful (n  = 22 out of 24) and had regret scores significantly less than neutral regret, regardless of their test results (Class 1: p  
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.5047